Imagine if the time of day you received cancer treatment could make a significant difference in your outcome. It sounds almost too good to be true, but recent research suggests that this could be a game-changer.
Researchers conducted an intriguing experiment, gathering lung cancer patients and dividing them into two groups. The only variable? The time of day they received their immunotherapy treatments. The results were eye-opening.
Patients who started their treatment in the morning experienced a remarkable five-month delay in cancer progression and lived almost a year longer on average. This finding challenges our understanding of cancer treatment and raises important questions.
But here's where it gets controversial: the reason behind this time-of-day effect remains a mystery. Experts are excited but cautious, as they grapple with the implications.
Dr. Zach Buchwald, an oncologist, describes the findings as "exceptionally compelling." He compares them to a revolutionary drug discovery, yet questions remain about the timing's impact on immunotherapy's long-term presence in the body.
Dr. Paolo Tarantino, a breast medical oncologist, goes further, calling it "possibly the most controversial finding in immune-oncology." The effect size is hard to believe, but the evidence from randomized-controlled trials is hard to ignore.
The study's authors, led by researchers in China, are calling for further investigation. Dr. Christoph Scheiermann, a co-author, acknowledges the need for replication across different cohorts and continents.
And this is where the story gets even more fascinating. Confirmatory studies are already underway, with one led by Dr. Buchwald and his team. They aim to test the timing theory on immunotherapy for melanoma patients, enrolling 100 participants across Emory and Massachusetts General Hospital.
The initial study, published in Nature Medicine, enrolled 210 non-small-cell lung cancer patients. The patients were randomly assigned to receive their first immunotherapy treatments either before or after 3 p.m., a cutoff chosen based on previous studies suggesting a daily slowdown of the immune system between 2 and 3 p.m.
The results were striking. Patients in the early treatment group survived nearly a year longer on average and experienced nearly double the time without cancer progression. At the end of the study, survival rates were significantly higher in the early treatment group.
Blood tests also revealed that patients receiving early treatment had more cancer-cell-killing immune cells.
Dr. Scheiermann's preclinical studies in mice provide a potential explanation. He found that specialized white blood cells, called T cells, are more active in the morning and cycle in and out of tumors throughout the day. Cancer cells, however, have evolved ways to suppress the immune response, effectively putting T cells to sleep.
Immunotherapy treatments, like PD-1 inhibitors, block this interaction, allowing T cells to recognize and fight cancer. The theory is that more T cells are physically present in the tumor during morning hours, leading to a stronger immune response when the drug is administered.
Interestingly, the timing of subsequent immunotherapy rounds doesn't seem to matter as much, according to Dr. Scheiermann.
Dr. Jeffrey Haspel, a pulmonologist studying circadian rhythms, adds that every layer of the immune system seems to have a biological rhythm. His team found that CAR-T therapy, which uses specially programmed T cells to fight blood cancers, also works better and has fewer side effects when given in the morning.
Other cancer drugs may also be sensitive to timing. A 2021 study found that half of the anticancer drugs screened were more effective at certain times of the day.
The implications of these findings are significant. As Dr. Haspel asks, "Is the juice worth the squeeze?" In other words, is the potential benefit of scheduling treatments at specific times worth the effort and disruption to the healthcare system?
For cancer immunotherapies, the answer seems to be a resounding yes. The size of the effect from morning scheduling is impressive, and further research could revolutionize the way we approach cancer treatment.
